Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 17

1.

Impact of drug policy on regional trends in ezetimibe use.

Lu L, Krumholz HM, Tu JV, Ross JS, Ko DT, Jackevicius CA.

Circ Cardiovasc Qual Outcomes. 2014 Jul;7(4):589-96. doi: 10.1161/CIRCOUTCOMES.114.001023. Epub 2014 Jun 3.

2.

Impact of medicare part D plan features on use of generic drugs.

Tang Y, Gellad WF, Men A, Donohue JM.

Med Care. 2014 Jun;52(6):541-8. doi: 10.1097/MLR.0000000000000142.

3.

Medicaid cost control measures aimed at second-generation antipsychotics led to less use of all antipsychotics.

Vogt WB, Joyce G, Xia J, Dirani R, Wan G, Goldman DP.

Health Aff (Millwood). 2011 Dec;30(12):2346-54. doi: 10.1377/hlthaff.2010.1296.

4.

Impact of prior authorization on the use and costs of lipid-lowering medications among Michigan and Indiana dual enrollees in Medicaid and Medicare: results of a longitudinal, population-based study.

Lu CY, Law MR, Soumerai SB, Graves AJ, LeCates RF, Zhang F, Ross-Degnan D, Adams AS.

Clin Ther. 2011 Jan;33(1):135-44. doi: 10.1016/j.clinthera.2011.01.012.

5.

Cost sharing, family health care burden, and the use of specialty drugs for rheumatoid arthritis.

Karaca-Mandic P, Joyce GF, Goldman DP, Laouri M.

Health Serv Res. 2010 Oct;45(5 Pt 1):1227-50. doi: 10.1111/j.1475-6773.2010.01117.x.

6.

Impact of two Medicaid prior-authorization policies on antihypertensive use and costs among Michigan and Indiana residents dually enrolled in Medicaid and Medicare: results of a longitudinal, population-based study.

Law MR, Lu CY, Soumerai SB, Graves AJ, LeCates RF, Zhang F, Ross-Degnan D, Adams AS.

Clin Ther. 2010 Apr;32(4):729-41; discussion 716. doi: 10.1016/j.clinthera.2010.04.007.

7.

The rise and fall of gabapentin for bipolar disorder: a case study on off-label pharmaceutical diffusion.

Fullerton CA, Busch AB, Frank RG.

Med Care. 2010 Apr;48(4):372-9. doi: 10.1097/MLR.0b013e3181ca404e.

8.

Prior authorization for biologic disease-modifying antirheumatic drugs: a description of US Medicaid programs.

Fischer MA, Polinski JM, Servi AD, Agnew-Blais J, Kaci L, Solomon DH.

Arthritis Rheum. 2008 Nov 15;59(11):1611-7. doi: 10.1002/art.24191.

9.

Medicaid prescription formulary restrictions and arthritis treatment costs.

Johnson TJ, Stahl-Moncada S.

Am J Public Health. 2008 Jul;98(7):1300-5. doi: 10.2105/AJPH.2007.118133. Epub 2008 May 29.

10.

Impact of Medicaid prior authorization requirement for COX-2 inhibitor drugs in Nebraska.

Siracuse MV, Vuchetich PJ.

Health Serv Res. 2008 Feb;43(1 Pt 2):435-50. doi: 10.1111/j.1475-6773.2007.00766.x.

11.
13.

The impact of reference pricing of nonsteroidal anti-inflammatory agents on the use and costs of analgesic drugs.

Grootendorst PV, Marshall JK, Holbrook AM, Dolovich LR, O'Brien BJ, Levy AR.

Health Serv Res. 2005 Oct;40(5 Pt 1):1297-317.

14.
15.

Pharmacy utilization and the Medicare Modernization Act.

Maio V, Pizzi L, Roumm AR, Clarke J, Goldfarb NI, Nash DB, Chess D.

Milbank Q. 2005;83(1):101-30. Review.

16.

From physician to consumer: the effectiveness of strategies to manage health care utilization.

Flynn KE, Smith MA, Davis MK.

Med Care Res Rev. 2002 Dec;59(4):455-81.

17.
Items per page

Supplemental Content

Write to the Help Desk